UNSPSC 51141563: Lacosamide

This classification denotes an anticonvulsant agent with the molecular formula C13H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 563KS2PQY5, chemically known as 2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide, (2r)- but generally known as lacosamide, which bears US NIH Compound Identifier 219078. European Medicines Agency schedules Lacosamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25407.

UNSPSC 51141563 Lacosamide is a Commodity code that maps to pharmaceutical products, but the recent state and local procurement activity under this code does not align with lacosamide specifically. Seminole County, Florida's IFB60459723LAS solicitation, posted June 30, 2026 with a response deadline of July 26, 2026, sought naloxone and drug deactivation systems—opioid-antagonist medications and harm-reduction equipment—rather than lacosamide, an antiepileptic drug. The mismatch between the code's nominal scope and the actual procurement posted suggests the code sees little relevant recent activity in state and local markets, or that the opportunity was tagged incorrectly at the commodity level.

Seminole County's procurement calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, with an initial two-year term and one-year renewal option. The solicitation was issued as an IFB with electronic bid submission, drug-free workplace and E-Verify compliance required, and potential FEMA funding introducing additional federal compliance obligations. The county has confirmed no explicit set-aside designations for this procurement. Without additional recent opportunities under the lacosamide code itself, activity cannot be characterized across geographies or issuing-body types at this time.